| Literature DB >> 31273955 |
Seyedeh Zahra Bakhti1, Saeid Latifi-Navid1, Saber Zahri1, Abbas Yazdanbod2.
Abstract
Iran is a high-risk country for cardia gastric adenocarcinoma (CGA) in Central Asia, with an incidence rate five times the average global rate, and shows a high infection rate for Helicobacter pylori (69%). The aim was to examine the associations of multiple H. pylori cagPAI genotypes (ie cagH, cagL, cagG, and orf17) with the risk of CGA, non-CGA, and different histological types of GA in Iran. A large number of H. pylori strains (N = 336) were successfully cultured and genotyped. Histopathological evaluations were performed. The analysis showed an inverse association between the cagH+ genotype and the risk of CGA and intestinal-type gastric adenocarcinoma (IGA) (adjusted ORs; 0.312 and 0.283, respectively), where the controls were nontumors. The orf17+ genotype decreased the risk of non-CGA and diffuse-type gastric adenocarcinoma (DGA)(adjusted ORs; 0.310 and 0.356, respectively). When the controls were those with nonatrophic gastritis, the cagG+ genotype was negatively associated with the risk of CGA, non-CGA, IGA, and DGA (adjusted ORs; 0.324, 0.366, 0.306, and 0.303, respectively). We did not find such a significant association for the cagL+ genotype in multiple logistic regression analysis. Combination of the vacA c2 and cagPAI genotypes further decreased the risk estimates for GAs. This study showed the reverse association of H. pylori cagPAI genotypes-cagH+ and cagG+ -with the risk of CGA in male patients aged ≥ 55 in Iran. Presence of the vacA c2 genotype in combination with cagPAI genotypes showed strong inverse associations with the risk of CGA and non-CGA. These findings may reveal a coordinated relationship between the vacA c2 and cagPAI genotypes.Entities:
Keywords: zzm321990Helicobacter pylorizzm321990; CGA; DGA; IGA; cagPAI genotypes; vacA c2
Mesh:
Substances:
Year: 2019 PMID: 31273955 PMCID: PMC6712521 DOI: 10.1002/cam4.2390
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Characteristics of patients enrolled in this study
| Characteristics | No. of patients (%) |
|---|---|
| Age groups | |
| ≥55 | 164/336 (48.8) |
| <55 | 170/336 (50.6) |
| No data | 2/336 (0.6) |
| Sex groups | |
| Males | 217/336 (64.6) |
| Females | 119/336 (36.4) |
| Types of gastroduodenal diseases | |
| Control | 209/336 (62.2) |
| Nonatrophic gastritis | 153/209 (73.2) |
| Peptic ulcer | 56/209 (26.8) |
| Case | 127/336 (37.8) |
| Cardia gastric adenocarcinoma | 56/127 (44.1) |
| Non‐cardia gastric adenocarcinoma | 66/127 (52.0) |
| Unspecified | 5/127 (3.9) |
| Intestinal‐type adenocarcinoma | 75/127 (59.1) |
| Diffuse‐type adenocarcinoma | 39/127 (30.7) |
| Mucin producing‐type adenocarcinoma | 5/127 (3.9) |
| Signet ring‐type adenocarcinoma | 4/127 (3.1) |
| Adenocarcinoma, poorly differentiated | 3/127 (2.4) |
| Adenocarcinoma, moderate differentiation | 1/127 (0.8) |
| Total | 336/336 (100) |
Risk estimates for CGA, NCGA, IGA, and DGA in relation to Helicobacter pylori cagPAI genotypes in a simple logistic regression analysis, where the controls were nontumors
| Genotypes |
Control | Cardia gastric adenocarcinoma | Non‐cardia gastric adenocarcinoma | Intestinal‐type adenocarcinoma | Diffuse‐type adenocarcinoma | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Case = 56 | Q‐value | OR | 95% CI |
Case = 66 | Q‐value | OR | 95% CI |
Case = 75 | Q‐value | OR | 95% CI |
Case = 39 | Q‐value | OR | 95% CI | ||
|
| |||||||||||||||||
|
| 131 (62.7) | 17 (30.4) |
|
|
| 23 (34.8) |
|
|
| 21 (28.0) |
|
|
| 15 (38.5) |
|
|
|
|
| 78 (37.3) | 39 (69.6) | 1 (ref) | 1 (ref) | 1 (ref) | 43 (65.2) | 1 (ref) | 1 (ref) | 1 (ref) | 54 (72.0) | 1 (ref) | 1 (ref) | 1 (ref) | 24 (61.5) | 1 (ref) | 1 (ref) | 1 (ref) |
|
| |||||||||||||||||
|
| 179 (85.6) | 37 (66.1) |
|
|
| 44 (66.7) |
|
|
| 50 (66.7) |
|
|
| 27 (69.2) |
|
|
|
|
| 30 (14.4) | 19 (33.9) | 1 (ref) | 1 (ref) | 1 (ref) | 22 (33.3) | 1 (ref) | 1 (ref) | 1 (ref) | 25 (33.3) | 1 (ref) | 1 (ref) | 1 (ref) | 12 (30.8) | 1 (ref) | 1 (ref) | 1 (ref) |
|
| |||||||||||||||||
|
| 152 (72.7) | 28 (50.0) |
|
|
| 29 (43.9) |
|
|
| 33 (44.0) |
|
|
| 17 (43.6) |
|
|
|
|
| 57 (27.3) | 28 (50.0) | 1 (ref) | 1 (ref) | 1 (ref) | 37 (56.1) | 1 (ref) | 1 (ref) | 1 (ref) | 42 (56.0) | 1 (ref) | 1 (ref) | 1 (ref) | 22 (56.4) | 1 (ref) | 1 (ref) | 1 (ref) |
|
| |||||||||||||||||
|
| 133 (63.6) | 19 (33.9) |
|
|
| 24 (36.4) |
|
|
| 26 (34.7) |
|
|
| 16 (41.0) |
|
|
|
|
| 76 (36.4) | 37 (66.1) | 1 (ref) | 1 (ref) | 1 (ref) | 42 (63.6) | 1 (ref) | 1 (ref) | 1 (ref) | 49 (65.3) | 1 (ref) | 1 (ref) | 1 (ref) | 23 (59.0) | 1 (ref) | 1 (ref) | 1 (ref) |
Non tumors.
False discovery rate‐adjusted P‐value.
Odds ratio.
Confidence interval.
Boldface data indicate statistically significant results.
Risk estimates for CGA, NCGA, IGA, and DGA in relation to H. pylori cagPAI genotypes in a simple logistic regression analysis, where the controls were those with non‐atrophic gastritis
| Genotypes | Control | Cardia gastric adenocarcinoma | Non‐cardia gastric adenocarcinoma | Intestinal‐type adenocarcinoma | Diffuse‐type adenocarcinoma | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case = 56 No.(%) | Q‐value | OR | 95% CI | Case = 66 No.(%) | Q‐value | OR | 95% CI | Case = 75 No.(%) | Q‐value | OR | 95% CI | Case = 39 No.(%) | Q‐value | OR | 95% CI | ||
|
| |||||||||||||||||
|
| 89(58.2) | 17(30.4) |
|
|
| 23(34.8) |
|
|
| 21(28.0) |
|
|
| 15(38.5) | 5.9e‐2 | 0.449 | 0.219‐0.924 |
|
| 64(41.8) | 39(69.6) | 1(ref) | 1(ref) | 1(ref) | 43(65.2) | 1(ref) | 1(ref) | 1(ref) | 54(72.0) | 1(ref) | 1(ref) | 1(ref) | 24(61.5) | 1(ref) | 1(ref) | 1(ref) |
|
| |||||||||||||||||
|
| 124(81.0) | 37(66.1) |
|
|
| 44(66.7) |
|
|
| 50(66.7) |
|
|
| 27(69.2) | 1.1e‐1 | 0.526 | 0.239‐1.161 |
|
| 29(19.0) | 19(33.9) | 1(ref) | 1(ref) | 1(ref) | 22(33.3) | 1(ref) | 1(ref) | 1(ref) | 25(33.3) | 1(ref) | 1(ref) | 1(ref) | 12(30.08 | 1(ref) | 1(ref) | 1(ref) |
|
| |||||||||||||||||
|
| 114(74.5) | 28(50.0) |
|
|
| 29(43.9) |
|
|
| 33(44.0) |
|
|
| 17(43.6) |
|
|
|
|
| 39(25.5) | 28(50.0) | 1(ref) | 1(ref) | 1(ref) | 37(56.1) | 1(ref) | 1(ref) | 1(ref) | 42(56.0) | 1(ref) | 1(ref) | 1(ref) | 22(56.4) | 1(ref) | 1(ref) | 1(ref) |
|
| |||||||||||||||||
|
| 89(58.2) | 19(33.9) |
|
|
| 24(36.4) |
|
|
| 26(34.7) |
|
|
| 16(41.0) | 7.6e‐2 | 0.500 | 0.245‐1.022 |
|
| 64(41.8) | 37(66.1) | 1(ref) | 1(ref) | 1(ref) | 42(63.6) | 1(ref) | 1(ref) | 1(ref) | 49(65.3) | 1(ref) | 1(ref) | 1(ref) | 23(59.0) | 1(ref) | 1(ref) | 1(ref) |
aNon‐atrophic gastritis; bFalse discovery rate‐adjusted P‐value; cOdds ratio; dConfidence interval; eBoldface data indicate statistically significant results.
Age‐ and sex‐adjusted risk for CGA, NCGA, IGA, and DGA in relation to Helicobacter pylori cagPAI genotypes in a multiple logistic regression analysis
| Genotypes | Cardia gastric adenocarcinoma | Non‐cardia gastric adenocarcinoma | Intestinal‐type adenocarcinoma | Diffuse‐type adenocarcinoma | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| OR | 95% CI |
| OR | 95% CI |
| OR | 95% CI |
| OR | 95% CI | |
| Gastric adenocarcinoma vs nontumors | ||||||||||||
|
| 0.002 | 0.312 | 0.150‐0.651 | — | — | — | 0.000 | 0.283 | 0.148‐0.543 | — | — | — |
|
| — | — | — | 0.001 | 0.310 | 0.158‐0.607 | — | — | — | 0.016 | 0.356 | 0.154‐0.826 |
| Gastric adenocarcinoma vs nonatrophic gastritis | ||||||||||||
|
| 0.009 | 0.324 | 0.139‐0.759 | 0.007 | 0.366 | 0.175‐0.762 | 0.001 | 0.306 | 0.150‐0.625 | 0.015 | 0.303 | 0.116‐0.790 |
Odds ratio.
Confidence interval.
Risk estimates for CGA, NCGA, IGA, and DGA in relation to Helicobacter pylori combination genotypes in a simple logistic regression analysis, where the controls were nontumors
| Genotypes |
Control | Cardia gastric adenocarcinoma | Non‐cardia gastric adenocarcinoma | Intestinal‐type adenocarcinoma | Diffuse‐type adenocarcinoma | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Case = 36 | Q‐value | OR | 95% CI |
Case = 45 |
| OR | 95% CI |
Case = 52 |
| OR | 95% CI |
Case = 25 |
| OR | 95% CI | ||
|
| 93(53.4) | 4(11.1) |
|
|
| 6(13.3) |
|
|
| 6(11.5) |
|
|
| 4(16.0) |
|
|
|
|
| 120(69.0) | 10 (27.8) |
|
|
| 9(20.0) |
|
|
| 13(25.0) |
|
|
| 4(16.0) |
|
|
|
|
| 98(56.3) | 9(25.0) |
|
|
| 6(13.3) |
|
|
| 9(17.3) |
|
|
| 4(16.0) |
|
|
|
|
| 98(56.3) | 5(13.9) |
|
|
| 6(13.3) |
|
|
| 6(11.5) |
|
|
| 4(16.0) |
|
|
|
Non tumors.
False discovery rate‐adjusted P‐value.
Odds ratio.
Confidence interval
Boldface data indicate statistically significant results.
Risk estimates for CGA, NCGA, IGA, and DGA in relation to Helicobacter pylori combination genotypes in a simple logistic regression analysis, where the controls were those with nonatrophic gastritis
| Genotypes |
Control | Cardia gastric adenocarcinoma | Non‐cardia gastric adenocarcinoma | Intestinal‐type adenocarcinoma | Diffuse‐type adenocarcinoma | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Case = 36 | Q‐value | OR | 95% CI |
Case = 45 |
| OR | 95% CI |
Case = 52 |
| OR | 95% CI |
Case = 25 |
| OR | 95% CI | ||
|
| 61(50.8) | 4(11.1) |
|
|
| 6(13.3) |
|
|
| 6(11.5) |
|
|
| 4(16.0) |
|
|
|
|
| 79(65.8) | 10 (27.8) |
|
|
| 9(20.0) |
|
|
| 13(25.0) |
|
|
| 4(16.0) |
|
|
|
|
| 70(58.3) | 9(25.0) |
|
|
| 6(13.3) |
|
|
| 9(17.3) |
|
|
| 4(16.0) |
|
|
|
|
| 64(53.3) | 5(13.9) |
|
|
| 6(13.3) |
|
|
| 6(11.5) |
|
|
| 4(16.0) |
|
|
|
Nonatrophic gastritis.
False discovery rate‐adjusted P‐value.
Odds ratio.
Confidence interval.
Boldface data indicate statistically significant results.